Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Mathews, Vikram ^a   Chendamarai, Ezhilarasi ^a   George, Biju ^a   Viswabandya, Auro ^a   Srivastava, Alok ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878562951     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.056     Document Type: Article

References (70)

1. DM. J. A history of the use of arsenicals in man. J R Soc Med. 1993;86:287-289. PMid:8505753 PMCid:1294007
2. Zhang TD. [Treatment of acute granulocytic leukemia with "Ai ling No. 1"--clinical analysis and experimental research]. Zhong Xi Yi Jie He Za Zhi. 1984;4:19-20. PMid:6233032
3. Zhang P WS, Hu LH, Shi FD, Giu FQ, Hong GJ et al. Treatment of acute promyelocytic leukemia with arsenic trioxide injection (713): Clinical observations and study of action mode. Chin J Hematol. 1996;17:58-60.
4. Sun HD ML, Hu XC, Zhang TD. Thirty two cases of treating acute promyelocytic leukemia by Ailing I therapy combined with syndrome differentiation treatment of traditional Chinese medicine. Chin J Comb Trad Chin Med West Med. 1992;1996:170-171.
5. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052-1061. PMid:8704214
6. Chen GQ, Shi XG, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997;89:3345-3353. PMid:9129041
7. Tang W, Chen G, Shi G. [Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line]. Zhonghua Yi Xue Za Zhi. 1997;77:509-512.
8. Chen Z, Wang ZY, Chen SJ. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther. 1997;76:141-149. http://dx.doi.org/10.1016/S0163-7258(97)00090-9
9. Zheng X, Seshire A, Ruster B, et al. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. Haematologica. 2007;92:323-331. http://dx.doi.org/10.3324/haematol.10541 PMid:17339181
10. Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011;117:5795-5802. http://dx.doi.org/10.1182/blood-2011-02-329367 PMid:21444912
11. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354-3360. PMid:9129042
12. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341-1348. http://dx.doi.org/10.1056/NEJM199811053391901 PMid:9801394
13. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol. 2004;17:95-103. http://dx.doi.org/10.1021/tx0341714 PMid:14727923
14. Sweeney CJ, Takimoto C, Wood L, et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol. 2010;66:345-356. http://dx.doi.org/10.1007/s00280-009-1169-4 PMid:19911123
15. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-3871. http://dx.doi.org/10.1200/JCO.2010.28.5031 PMid:20644086
16. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632. http://dx.doi.org/10.1182/blood-2005-08-532 PMid:16352810
17. Mathews V, Desire S, George B, et al. Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. Leukemia. 2006;20:881-883. http://dx.doi.org/10.1038/sj.leu.2404165 PMid:16525498
18. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia. J Clin Oncol. 2011.
19. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115:1697-1702. http://dx.doi.org/10.1182/blood-2009-07-230805 PMid:20029047
20. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett. 2000;112-113:209-217. http://dx.doi.org/10.1016/S0378-4274(99)00271-4
21. Goering PL AH, Mass MJ et al. The Enigma of Arsenic Carcinogenesis: Role of metabolism. Toxicological Sciences. 1999;49:5-14. http://dx.doi.org/10.1093/toxsci/49.1.5 PMid:10367337
22. Brouwer OF OW, Edelbroek PM et al. Inceased neurotoxicity of arsenic in MTHFR deficiency. Clin Neurol Neurosurg. 1992;94:307-310. http://dx.doi.org/10.1016/0303-8467(92)90179-7
23. Pickett CB. Glutathione S-Transferases: Gene structure, Regulation and Biological Function. Ann Rev Biochem. 1989;58:743-764. http://dx.doi.org/10.1146/annurev.bi.58.070189.003523 PMid:2673020
24. Chiou HY, Hsueh, Y.M, Hseih, L.L et al. Arsenic methylation capacity, body retention and null genotypes of glutathione Stransferases M1 and T1 among current arsenic exposed residents of Taiwan. Mutat Res. 1997;386:197-207. http://dx.doi.org/10.1016/S1383-5742(97)00005-7
25. Naranmandura H, Carew MW, Xu S, et al. Comparative Toxicity of Arsenic Metabolites in Human Bladder Cancer EJ-1 Cells. Chem Res Toxicol;24:1586-1596. PMid:21815631
26. Zhang P WS, Hu LH, Shi FD, Giu FQ, Hong GJ et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol. 1996;2:58.
27. Sun HD ML, Hu XC, Zhang TD. Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat Chin & West Med. 1992;12:170.
28. Treleaven J, Meller S, Farmer P, Birchall D, Goldman J, Piller G. Arsenic and Ayurveda. Leuk Lymphoma. 1993;10:343-345. http://dx.doi.org/10.3109/10428199309148558 PMid:7693104
29. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504-510. http://dx.doi.org/10.1200/JCO.2008.18.6130 PMid:19075265
30. Gore SD, Gojo I, Sekeres MA, et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol. 2010;28:1047-1053. http://dx.doi.org/10.1200/JCO.2009.25.5158 PMid:20085935 PMCid:2834430
31. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of alltrans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009;106:3342-3347. http://dx.doi.org/10.1073/pnas.0813280106 PMid:19225113 PMCid:2651325
32. Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2000;133:881-885. PMid:11103058
33. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98:266-271. http://dx.doi.org/10.1182/blood. V98.2.266 PMid:11435292
34. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001;97:1514-1516. http://dx.doi.org/10.1182/blood. V97.5.1514 PMid:11222403
35. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324. PMid:10552940
36. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396-2410. http://dx.doi.org/10.1200/JCO.2005.10.217 PMid:15800332
37. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324. PMid:10552940
38. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci U S A. 1998;95:8103-8107. http://dx.doi.org/10.1073/pnas.95.14.8103
39. Cuzick J, Evans S, Gillman M, Price Evans DA. Medicinal arsenic and internal malignancies. Br J Cancer. 1982;45:904-911. http://dx.doi.org/10.1038/bjc.1982.143 PMid:6212076 PMCid:2011026
40. Au WY, Kumana CR, Lam CW, et al. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia. Leuk Res. 2007;31:105-108. http://dx.doi.org/10.1016/j.leukres.2006.03.018 PMid:16725199
41. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2010;29:495-503. http://dx.doi.org/10.1200/JCO.2010.32.1067 PMid:21220600
42. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113:1875-1891. http://dx.doi.org/10.1182/blood-2008-04-150250 PMid:18812465
43. Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. Natl Med J India. 2001;14:215-222. PMid:11547528
44. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505-2515. http://dx.doi.org/10.1182/blood-2007-07-102798 PMid:18299451
45. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood. 1999;94:12-22. PMid:10381493
46. Mrozek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24:17-31. PMid:9045301
47. Slack JL, Arthur DC, Lawrence D, et al. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:1786-1795. PMid:9164186
48. De Botton S, Chevret S, Sanz M, et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000;111:801-806. http://dx.doi.org/10.1046/j.1365-2141.2000.02442.x PMid:11122141
49. Mathews V, Thomas M, Srivastava VM, George B, Srivastava A, Chandy M. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994-995 http://dx.doi.org/10.3324/haematol.10802 PMid:17606455
50. Gilliland DG. FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitors. Best Pract Res Clin Haematol. 2003;16:409-417. http://dx.doi.org/10.1016/S1521-6926(03)00063-X
51. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542. http://dx.doi.org/10.1182/blood-2002-02-0492 PMid:12176867
52. Marasca R, Maffei R, Zucchini P, et al. Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status. Leukemia. 2006 Jan;20(1):103-14. PMid:16270043
53. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768-3776 http://dx.doi.org/10.1182/blood-2005-04-1746 PMid:16105978
54. Callens C, Chevret S, Cayuela JM, et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia. 2005;19:1153-1160. http://dx.doi.org/10.1038/sj.leu.2403790 PMid:15889156
55. Chillon MC, Santamaria C, Garcia-Sanz R, et al. Long FLT3 internal tandem duplications and reduced PML-RARalpha expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients. Haematologica. 2010;95:745-751. http://dx.doi.org/10.3324/haematol.2009.015073 PMid:20133893 PMCid:2864380
56. Thirugnanam R, George B, Chendamarai E, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxidebased regimen. Biol Blood Marrow Transplant. 2009;15:1479-1484 http://dx.doi.org/10.1016/j.bbmt.2009.07.010 PMid:19822309
57. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002;2:705-713. http://dx.doi.org/10.1038/nrc887 PMid:12209159
58. Coe E, Schimmer AD. Catalase activity and arsenic sensitivity in acute leukemia. Leuk Lymphoma. 2008;49:1976-1981. http://dx.doi.org/10.1080/10428190802353617
59. Zhou X, Sun H, Ellen TP, Chen H, Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis. 2008;29:1831-1836 http://dx.doi.org/10.1093/carcin/bgn063 PMid:18321869 PMCid:2722848
60. Davison K, Mann KK, Waxman S, Miller WH, Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood. 2004;103:3496-3502. http://dx.doi.org/10.1182/blood-2003-05-1412 PMid:14701702
61. Zhu J, Zhou J, Peres L, et al. A sumoylation site in PML/RARA is essential for leukemic transformation. Cancer Cell. 2005;7:143-153. http://dx.doi.org/10.1016/j.ccr.2005.01.005 PMid:15710327
62. Lallemand-Breitenbach V, Jeanne M, Benhenda S, et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008;10:547-555 http://dx.doi.org/10.1038/ncb1717 PMid:18408733
63. Ling YH, Jiang JD, Holland JF, Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol. 2002;62:529-538. http://dx.doi.org/10.1124/mol.62.3.529 PMid:12181429
64. Kapahi P, Takahashi T, Natoli G, et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000;275:36062-36066. http://dx.doi.org/10.1074/jbc. M007204200 PMid:10967126
65. Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002;1:851-860. PMid:12492118
66. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces doseand time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000;96:1525-1530. PMid:10942401
67. Jeanne M, Lallemand-Breitenbach V, Ferhi O, et al. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18:88-98. http://dx.doi.org/10.1016/j.ccr.2010.06.003 PMid:20609355
68. Li L, Wang J, Ye RD, et al. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol. 2008;217:486-493. http://dx.doi.org/10.1002/jcp.21523 PMid:18636556
69. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999;93:268-277. PMid:9864170
70. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116:3751-3757. http://dx.doi.org/10.1182/blood-2010-02-269621 PMid:20705755 PMCid:2981533